Skip to main content
Toggle navigation
Login
Search
Home
Tweets by 2022 IKCS: Europe
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Real-world Evidence
Home
Real-world Evidence
Real-world Evidence
Type here to filter the list
4: ‘Real world’ impact of immune checkpoint inhibitors (ICI) on survival in metastatic renal cell cancer (mRCC)
Favorite
12: Efficacy of frontline combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS)
Favorite
13: Complete Responses with first line (1L) antiangiogenic monotherapy in Spanish patients with metastatic renal cell carcinoma (mRCC). The ATILA study
Favorite
14: Real-World Clinical Outcomes of tivozanib as first-line treatment of metastatic renal cell carcinoma in Germany
Favorite
15: Image-guided robotic radiosurgery for the treatment of metastases of renal cell carcinoma.
Favorite
16: Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT
Favorite
17: Real-world clinical characteristics and treatment patterns in patients with advanced renal cell carcinoma treated with first-line immunotherapy + axitinib in Germany
Favorite